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A b s t r a c t
Background: Subcutaneous implantable cardioverter-defibrillator (S-ICD) may be an alternative to transvenous ICD (TV-ICD). 
Aim: We sought to evaluate factors determining the choice of S-ICD vs. TV-ICD in Polish patients in comparison to other 
European countries. 
Methods: All consecutive patients who underwent TV-ICD or S-ICD implantation in centres participating in the European 
Heart Rhythm Association prospective snapshot survey were included. 
Results: During an eight-week study period, 429 patients were recruited, including 136 (31.7%) ICD patients from Poland 
(eight with S-ICD). In comparison to other European centres, the proportion of S-ICD implantations in Poland was lower (7% 
vs. 26%, p < 0.001), whereas the ratio of cardiac resynchronisation therapy defibrillator implantations was higher (43% vs. 26%; 
p < 0.001). Subjects receiving S-ICD in Poland were more often over 75 years old (25% vs. 0%, p < 0.001), in New York Heart 
Association class II (87.5% vs. 29.4%, p = 0.001), with chronic kidney disease (37.5% vs. 5.9%, p = 0.003), and with lower 
left ventricular ejection fraction (32% [14%–50%] vs. 50% [25%–60%], p = 0.04), compared to other European countries. Ad-
ditionally, in comparison to subjects from other European centres, Polish patients were significantly more often implanted with 
S-ICD due to prior infection (37.5% vs. 1.5%, p < 0.001) and a lack of venous access (25% vs. 0%, p < 0.001), whereas the 
largest subset of patients in other European countries were implanted with S-ICD because of young age (50% vs. 25%, p = NS).
Conclusions: The main reasons leading to S-ICD implantations in Polish patients differ from the indications adopted in other 
European countries. In Poland, patients referred for TV-ICD or S-ICD implantation had more advanced heart failure and more 
comorbidities in comparison to subjects from other European countries. S-ICD is still underused in Polish patients. 
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INTRODUCTION
The role of the implantable cardioverter-defibrillator (ICD) in 
reducing the rate of sudden cardiac death (SCD) in patients 
at risk of life-threatening ventricular tachyarrhythmias has 
been demonstrated in numerous clinical trials [1, 2]. Despite 
recent developments in technology, device-related complica-
tions, especially those connected with transvenous leads, are 
frequent and are associated with significant morbidity and 
mortality [3–5]. The purpose of developing an entirely sub-
cutaneous ICD (S-ICD) was to avoid endocardial leads, and 
thus to eliminate the risk of lead-related complications. This 
new technology received a Conformité Européene (CE) mark 
in Europe in 2009 [6]. Subsequent clinical trials have dem-
onstrated that S-ICDs are safe and effective in the treatment 
of ventricular arrhythmias, with rates of inappropriate shocks 
comparable to those of transvenous ICDs (TV-ICDs) [7–9]. 
According to the guidelines, S-ICD may be an alternative to 
TV-ICD in patients with venous access problems, after removal 
of a classic ICD due to infections, or in young patients in whom 
a very long-term need for ICD is anticipated [10]. At the same 
time, the guidelines state that S-ICD might be an alternative 
to TV-ICD only in patients in whom pacing (for bradycardia or 
antitachycardia) or cardiac resynchronisation therapy (CRT) is 
not needed [10]. The first S-ICD implantation in Poland took 
place in 2014 [11] and so far this therapy is reimbursed only 
if the rationale for the implantation of this particular device 
(rather than the transvenous one) can be provided by the 
attending physician. The factors that influence the choice 
to implant S-ICD, rather than TV-ICD in Poland are not fully 
known. The aim of our study was to evaluate the determinants 
of this decision among Polish physicians in comparison with 
other European countries. 
METHODS 
The data from the European Heart Rhythm Association (EHRA) 
prospective snapshot survey were used for the analysis. Ter-
tiary cardiac centres, in which both TV-ICDs and S-ICDs are 
routinely implanted and S-ICD implantations are reimbursed, 
participated voluntarily in this prospective EHRA survey. The 
data were collected via an internet-based electronic ques-
tionnaire designed by the EHRA Scientific Committee to 
gather information on ICD patients. All consecutive patients 
implanted with an ICD in the participating centres during 
an eight-week survey period were prospectively included in 
the study. The questionnaire was anonymous and consisted 
of 30 multiple-choice questions regarding the referral of the 
patient to a particular type of ICD and to periprocedural 
proceedings [12].
Statistical analysis
Continuous parameters were expressed as mean ± standard 
deviation or median and interquartile range if non-normally 
distributed, whereas categorical variables were expressed 
as numbers and percentages. The c2, Student t test, or 
Mann-Whitney U test was used to compare the groups, as 
appropriate. A p-value of < 0.05 was considered statistically 
significant. All statistical analyses were performed using the 
Statistica software package (versions 6.0 and 10.0, StatSoft 
Inc., Tulsa, OK, USA).
RESULTS
Participating centres
A total of 20 centres from six countries participated in this 
EHRA snapshot survey: eight from France, six from Poland, two 
from Germany, two from Italy, and one each from Austria and 
Switzerland. Of those centres, 18 were university hospitals, 
whereas two were private ones. Where needed, the approval 
of a Local Ethics Committee was obtained. 
Study population 
Between April and June 2017, a total of 429 consecutive 
patients were included into the survey; in 383 of them the 
device type was specified (307 had TV-ICD and 76 had 
S-ICD). Most of the participants were aged between 56 and 
65 years (28.5%) or between 66 and 75 years (25.7%). Ischae-
mic aetiology of heart failure (HF) was present in 55.4% of 
patients, and New York Heart Association (NYHA) functional 
class II prevailed (53%). The most common comorbidities were 
coronary artery disease (48%) and diabetes (28%) (Table 1). 
Patients in Poland vs. other European countries 
In total, 136 (31.7%) patients from Polish centres were in-
cluded, but the device type was specified for only 125 (91.9%) 
of them. 
The age of Polish patients ranged most commonly be-
tween 56 and 75 years (n = 81 [64.8%]), and 22% of them 
were older than 75 years. The dominant functional NYHA 
classes were II (50.4%) and III (41.6%). In comparison to 
other European patients, NYHA class I was less common in 
Polish ICD recipients (7.2% vs. 28.3%, p < 0.001), whereas 
NYHA class III was more commonly observed (16.7% in the 
remaining European participants, p < 0.001).
The mean left ventricular ejection fraction (LVEF) in Polish 
subjects was lower than in other European participants (27% 
[18%–35%] vs. 30% [20%–60%], p < 0.001) and the lack of 
any structural heart disease was observed less often (3.2% 
vs. 13.9%, p = 0.001). In comparison to other European 
centres, in Poland the devices were implanted more often 
for primary prevention of SCD (80% vs. 66.7%, p = 0.007). 
Atrial fibrillation at implantation was present in 20.7% of 
Polish patients referred for ICD — more often than among 
other Europeans subjects (11.2%, p = 0.02). Data on baseline 
characteristics of patients are shown in Table 1. 
ICD type in Poland vs. other European countries 
The device that was implanted the most often in Polish pa-
tients was a cardiac resynchronisation therapy defibrillator 
(CRT-D; n = 54 [43%]), followed by a single-chamber ICD 
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(ICD-VR; n = 44 [35%]) and a dual-chamber ICD (ICD-DR; 
n = 19 [15%]). Only eight (7%) Polish subjects had an S-ICD 
implanted during the eight-week survey period. In comparison 
to other European centres, the proportion of implanted S-ICDs 
in Poland was lower (7% vs. 26%, p < 0.001), whereas the ratio 
of CRT-D implantations was higher (43% vs. 26%; p < 0.001). 
The types of implanted ICDs are presented in Figure 1.
Polish vs. other European patients with S-ICD 
Polish patients with implanted S-ICDs were predomi-
nantly male (n = 6 [75%]), with ischaemic aetiology of HF 
(n = 5 [62.5%]) and there was only one (12.5%) patient 
without structural heart disease. 
In comparison to other European patients, Polish S-ICD 
recipients were more often at the age above 75 years (25% 
vs. 0%, p < 0.001), were less often in NYHA class I (12.5% 
vs. 67.7%, p = 0.002), but more often in NYHA class II (87.5% 
vs. 29.4%, p = 0.001).
The most common comorbidity in Polish patients was 
coronary artery disease (50%), followed by chronic kidney 
disease, which was more prevalent than in other European 
patients (37.5% vs. 5.9%, p = 0.003). Moreover, Polish S-ICD 
patients had significantly lower LVEF in comparison to subjects 
from other European centres (32% [14%–50%] vs. 50% 
[25%–60%], p = 0.04). The data on Polish and other European 
patients with implanted S-ICDs are summarised in Table 2. 
Factors leading to S-ICD or TV-ICD implantation  
in Poland vs. other European countries 
The main reasons leading to S-ICD implantations in Polish sub-
jects were associated with infections or electrode-related compli-
cations (i.e. previous device infection with removal; 37.5%) and 
anticipated lead-related complications in case of conventional 
ICD use (37.5%), elevated risk of infection (i.e. diabetes, renal 
failure; 25%), or no adequate venous access (25%). Conversely, 
the largest subset of patients in other European countries were 
implanted with S-ICDs because of young age (50%) and antici-
pated lead-related complications (26.5%). In comparison to other 
European subjects, Polish patients were significantly more often 
implanted with S-ICD due to lack of adequate venous access 
(25% vs. 0%, p < 0.001) and prior infection with device removal 
(37.5% vs. 1.5%, p < 0.001). The data on the indications for 
S-ICD implantation are summarised in Figure 2.
Economic issues and the need for CRT more often de-
termined the use of a conventional defibrillator rather than 
S-ICD in Polish patients. The need for pacing and the choice 






countries (n = 258)
p*
Age < 18 years 4 (1.0) 0 (0) 4 (1.6) 0.16
Age > 75 years 69 (17.7) 27 (21.6) 42 (16.3) 0.20
Women 92 (23.6) 33 (26.4) 58 (22.5) 0.39
NYHA I 83 (21.3) 9 (7.2) 73 (28.3) < 0.001
NYHA II 206 (52.9) 63 (50.4) 139 (53.9) 0.52
NYHA III 96 (24.7) 52 (41.6) 43 (16.7) < 0.001
NYHA IV 4 (1.0) 1 (8%) 3 (1.2) 0.74
Ischaemic HF aetiology 191 (49.9) 71 (56.8) 120 (46.5) 0.06
No structural heart disease 40 (10.4) 4 (3.2) 36 (13.9) 0.001
Primary prevention of SCD 272 (70) 100 (80) 172 (66.7) 0.007
Diabetes mellitus 108 (28.2) 46 (36.8) 62 (24) 0.009
Chronic renal disease 55 (14.4) 23 (18.4) 32 (12.4) 0.12
COPD 35 (9.1) 16 (12.8) 19 (7.4) 0.08
AF/AFL 54 (14.5) 25 (20.7) 29 (11.2) 0.02
Sick sinus syndrome at implantation 11 (2.9) 7 (5.6) 4 (1.6) 0.03
High-degree AV block at implantation 7 (1.9) 2 (1.6) 5 (1.9) 0.82
LVEF [%] 30 (20–60) 27 (18–35) 30 (20–60) < 0.001
Left bundle branch block 64 (17.2) 28 (23.1) 36 (13.9) 0.04
QRS 120–150 ms 63 (16.9) 18 (14.9) 45 (17.4) 0.45
QRS > 150 ms 110 (29.5) 54 (44.6) 56 (21.7) < 0.001
Continuous variables presented as median (interquartile range), categorical variables as numbers (percentages). *p for comparison of Polish 
patients vs. other European patients. AF — atrial fibrillation; AFL — atrial flutter; AV — atrioventricular; COPD — chronic obstructive pulmonary 
disease; HF — heart failure; LVEF — left ventricular ejection fraction; NYHA — New York Heart Association; SCD — sudden cardiac death
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of an antitachycardia pacing (ATP) option were the other 
two most frequent reasons influencing the device selection. 
When compared to Poland, in other European countries 
the economic factors were significantly less important in the 
decision-making process (3.9% vs. 32.8%, p < 0.001). The 
choice of an ATP option was the reason for more frequent 
favouring of conventional defibrillator implantation in other 
European countries (36.4% vs. 21.6%, p = 0.003; Fig. 3A). 






countries (n = 68)
p*
Age < 18 years 2 (2.6) 0 (0) 2 (2.9) 0.62
Age > 75 years 2 (2.6) 2 (25) 0 (0) < 0.001
Women 24 (31.6) 2 (25) 22 (32.4) 0.67
NYHA I 47 (61.8) 1 (12.5) 46 (67.7) 0.002
NYHA II 27 (35.5) 7 (87.5) 20 (29.4) 0.001
NYHA III 2 (2.6) 0 (0) 2 (2.9) 0.62
NYHA IV 0 (0) 0 (0) 0 (0) –
Ischaemic HF aetiology 29 (38.2) 5 (62.5) 24 (35.3) 0.13
No structural heart disease 21 (27.6) 1 (12.5) 20 (29.4) 0.31
Primary prevention of SCD 49 (64.5) 6 (75) 43 (63.2) 0.51
Diabetes mellitus 11 (14.5) 2 (25) 9 (13.2) 0.37
Chronic renal disease 7 (9.2) 3 (37.5) 4 (5.9) 0.003
COPD 3 (3.9) 0 (0) 3 (4.4) 0.54
AF/AFL 6 (7.9) 2 (25) 4 (5.9) 0.06
Sick sinus syndrome at implantation 0 (0) 0 (0) 0 (0) –
High degree AV block at implantation 0 (0) 0 (0) 0 (0) –
LVEF [%] 40 (25–60) 32 (14–50) 50 (25–60) 0.04
Left bundle branch block 3 (3.9) 0 (0) 3 (4.4) 0.54
QRS 120–150 ms 14 (18.4) 1 (12.5) 13 (19.1) 0.65
QRS > 150 ms 1 (1.3) 1 (12.5) 0 (0) 0.003 
Continuous variables presented as median (interquartile range), categorical variables as numbers (percentages). *p for comparison of Polish  
patients vs. other European patients. Abbreviations — see Table 1
Figure 1. Devices implanted in Poland (A) vs. other European (B) centres. CRT-D — cardiac resynchronisation therapy defibrillator; 
ICD-DR — dual-chamber implantable cardioverter-defibrillator; ICD-VR — single-chamber implantable cardioverter-defibrillator, 
S-ICD — subcutaneous implantable cardioverter-defibrillator
A B
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Because there was a significant difference in the percentage 
of patients with sick sinus syndrome between Poland and 
other European countries (5.6% vs. 1.6%, p = 0.03), a sepa-
rate analysis of the factors leading to implantation of TV-ICD 
rather than S-ICD was performed, with the exclusion of these 
patients (Fig. 3B). 
DISCUSSION
The main findings of this sub-analysis are the following: 1) Pol-
ish patients referred for ICD implantation had more advanced 
HF and more comorbidities when compared to subjects from 
other European countries; 2) S-ICD is still underused in Po-
land; 3) the main reasons favouring conventional ICD over 
S-ICD in Polish centres were of economic nature; 4) the main 
reasons leading to S-ICD implantation in Polish subjects were 
associated with infections, electrode-related complications or 
lack of adequate venous access; 5) the distribution of device 
types was different in Poland as compared to other European 
countries, with a lower rate of S-ICD implantations and higher 
rate of CRT-D devices. 
This EHRA prospective multicentre snapshot survey was 
designed to recognise European practices in the manage-
ment of TV-ICD and S-ICD patients and recently provided 
an up-to-date overview of indications for ICD, periprocedural 
routines, and complications in European tertiary centres [12, 
13]. Our sub-analysis provides an additional important con-
temporary view on Polish patients undergoing ICD implan-
tation and examines the criteria that influence the choice 
between S-ICD and TV-ICD in Poland, in comparison to other 
European countries. 
The baseline characteristics of Polish ICD recipients 
were different from those of patients from other European 
countries. The crucial difference was a more advanced HF 
and more comorbidities. Polish patients undergoing ICD im-
plantation were older, more often in NYHA class III, with lower 
LVEF, and more often with left bundle branch block, diabetes 
mellitus, and atrial fibrillation. These differences in baseline 
characteristics were also observed in the exclusive analysis 
of the group of patients undergoing S-ICD implantation. The 
possible reasons for this discrepancy may depend on multiple 
factors. It was already reported that Polish patients at the time 
of HF diagnosis are younger and have higher LVEF, but are im-
planted significantly less frequently with devices such as ICD, 
CRT, and CRT-D, compared to HF patients in other European 
countries [14]. It seems that, even though HF is diagnosed at 
a relatively young age in Poland, the decision to implant the 
Figure 2. Reasons leading to the implantation of subcutaneous implantable cardioverter-defibrillator (S-ICD) in Polish subjects 
vs. other European patients (multiple answers). CKD — chronic kidney disease; DM — diabetes mellitus; LR — lead-related;  
TV-ICD — transvenous implantable cardioverter-defibrillator; *p < 0.05
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Figure 3. Reasons leading to the implantation of transvenous implantable cardioverter-defibrillator (TV-ICD) in Polish patients 
vs. other European patients (multiple answers). A. All patients; B. All patients apart from subjects with sick sinus syndrome.  
ATP — antitachycardia pacing; CRT — cardiac resynchronisation therapy; ECG — electrocardiogram; S-ICD — subcutaneous 
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device is postponed. There are several probable explanations 
for this phenomenon. As previously demonstrated, only 55% 
to 60% of patients with the indications for ICD or CRT were 
referred for device implantation, and in 40% to 44% of cases 
the procedure was not performed due to physician’s doubts 
or patient’s refusal [15]. The model of health care in Poland 
assumes that patients with diagnosed HF in whom pharmaco-
logical treatment was already established should be under the 
supervision of general practitioners (GPs), with only periodic 
consultations with a cardiologist. However, it was reported that, 
although HF pharmacotherapy prescribed by GPs is similar 
to the treatment recommended by cardiologists in Poland, 
the perception of indications for cardiac implantable devices 
differs substantially (outpatients treated by GPs less commonly 
receive ICDs and CRTs) [16]. What is more, since LVEF in Pol-
ish patients is higher at the time of HF diagnosis, a significant 
proportion of them do not initially have indications for an ICD. 
An excessive expectation for LVEF to improve with time might 
also play a role in deferring the decision to implant an ICD. 
Finally, a significant proportion of younger patients (greater 
than that of older subjects) refuse to be implanted with an ICD.
Our country-specific data show that the criteria de-
termining the choice between S-ICD and TV-ICD in Polish 
centres may differ from those used in other countries. This 
sub-analysis showed that the main reasons leading to the 
use of a conventional ICD instead of S-ICD in Poland were 
economic issues. All new technologies are expensive, and 
their reimbursement in Poland is restricted only to special 
cases. Our results demonstrate, however, that despite the 
above there are some groups of Polish patients in whom the 
S-ICD is preferred over the TV-ICD, although for different 
reasons than in other European countries. In Poland, the 
main reasons leading to S-ICD implantation were infections 
or electrode-related complications, such as previous device 
infections with removal, anticipated lead-related complica-
tions, high risk of infection, or inadequate venous access. This 
is in contrast with other European countries, where young age 
of patients was the most common reason for S-ICD use [12]. 
Problems with transvenous electrodes are the main drawbacks 
of TV-ICDs, and they were among the reasons to develop 
the S-ICD system. Subsequently, a body of clinical evidence 
has been gathered confirming that S-ICD technology is safe 
and that the midterm efficacy of this therapy is similar to that 
observed in TV-ICD studies [7, 8]. Consequently, the use of 
S-ICDs has spread widely, and subcutaneous devices have 
been implemented not only in patients with difficult venous 
access or after ICD infections, but also in those requiring 
long-term ICD therapy. Our sub-study showed that in Polish 
patients, S-ICD is an alternative to TV-ICD only in very selected 
cases: mainly when the TV-ICD has led to complications or 
if no venous access can be found. In other words, standard 
ICD is the first-line therapy and S-ICD is only chosen when 
the implantation of a TV-ICD is not possible. Probably due to 
economic reasons, this is in contrast to other European coun-
tries, where the new technology is penetrating daily practice 
to prevent complications caused by “older technologies.” 
On the other hand — putting the economic issues aside 
— the reasons for choosing the TV-ICD were quite similar in 
Poland and in other European centres. In over 83% of cases 
they were associated with the limitations of S-ICD systems, 
such as the need for pacing, CRT, and the possibility to deliver 
ATP. At present, S-ICD is not conventionally an option for 
patients who require permanent pacing; nonetheless, when 
combined with a transvenous pacemaker, such a combination 
is feasible [17–19].
Finally, the distribution of device types was different in 
Poland as compared to other European countries. The number 
of S-ICD implantations was lower, whereas the number of 
CRT-D devices was higher (reaching over 40% of all ICDs). 
In other European countries the proportions of ICD-VRs and 
S-ICDs were comparable. However, in Poland the number 
of implanted S-ICDs was significantly lower than the number 
of ICD-VRs, making up only one-sixth of all ICDs. Previously 
published data show that S-ICD technology penetrates clinical 
practice in Poland [20–22], but our analysis suggests that this 
process is slow; similar unfavourable trends were previously 
observed with the spreading adoption of conventional ICDs 
[23]. Looking at published data on feasibility and safety, as 
well as system performance and inappropriate shock rates, 
which were comparable with those reported for conventional 
ICDs, it seems justified to suppose that, in the absence of 
the need for pacing or CRT, S-ICD could gradually replace 
a considerable percentage of single- and dual-chamber 
TV-ICDs. This suggestion is supported by the European Society 
of Cardiology guidelines for the management of patients with 
ventricular arrhythmias and the prevention of SCD. These 
recommendations treat S-ICD as an alternative to TV-ICD 
in patients with an indication for ICD, when pacing therapy 
for bradycardia support, CRT, or ATP is not needed, and in 
young patients with a long-term need for ICD therapy. When 
looking at our data on the reasons for choosing TV-ICD instead 
of S-ICD, the need for pacing or CRT was comparable in 
Poland and other European countries, whereas the potential 
need for ATP was even more common in other European 
countries. Thus, the percentage of patients in whom S-ICD 
was not an option was probably comparable in Poland and 
other European countries. Lastly, CRT-Ds were implanted in 
a higher percentage of Polish patients when compared to 
other European countries. This might be the effect of differ-
ent baseline characteristics of Polish ICD recipients, who had 
more advanced HF and, probably, greater prevalence of wide 
QRS complex and left bundle branch block. 
Our sub-analysis of this EHRA prospective snapshot sur-
vey has several limitations. The main one is the small number 
of patients with implanted S-ICDs. On the other hand, this 
finding reflects the real life because the number of S-ICD 
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implantations in Poland is small, with only 15 patients having 
received this device in 2015 [24]. Secondly, participation in 
the survey was voluntary and based on high-volume centres; 
thus, generalisation of the results must be restricted to tertiary 
clinical centres. Lastly, the survey was based on data obtained 
from the questionnaire, which limited the answer options only 
to the most common ones. 
In conclusion, the main reasons leading to S-ICD implan-
tation in Polish patients differ from those adopted by other 
European countries. Polish patients referred for TV-ICDs and 
S-ICDs had more advanced HF and more comorbidities in 
comparison to subjects from other European centres. S-ICD 
is still underused in Poland. 
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